NovaBay Pharmaceuticals Inc (NBY)

[Minding]

NovaBay Pharmaceuticals, Inc. Analyst Rating Update

From http://thedailyrover.com/novabay-pharmaceuticals-inc-analyst-rating-update/

June 10, 2015 A+A-SHARE ON EMAILEMAILSHARE ON PRINTPRINT
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY): The Company shares has received a rating of Buy from 3 Wall Street Analysts. NovaBay Pharmaceuticals, Inc. shares have received a Mean Price Target of $1.72. According to the rating issued from 3 Wall Street Analysts, the High Price Target is seen at $2 while the Lower end of the Price Target is seen at $1.25. The Median Price Target is calculated at $1.9.

Many Wall Street Brokerage firms have commented on company shares. Maxim Group initiates coverage on NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY). In the latest research report, Maxim Group announces the target price to $2 per share on the counter. According to the latest information available, the shares are now rated Buy by the analysts at the agency.

NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) witnessed a decline in the market cap on Tuesday as its shares dropped 1.76% or 0.0154 points. After the session commenced at $0.9, the stock reached the higher end at $0.9 while it hit a low of $0.84. With the volume soaring to 360,793 shares, the last trade was called at $0.86. The company has a 52-week high of $1.3. The company has a market cap of $53 million and there are 61,198,000 shares in outstanding. The 52-week low of the share price is $0.42. The Company has disclosed insider buying and selling activities to the Securities Exchange, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Novabay Pharmaceuticals, Inc., Sieczkarek Mark M had purchased shares worth of $100,000 in a transaction dated on March 3, 2015. A total of 166,666 shares were purchased at a price of $0.6 per share. The information is based on open market trades at the market prices.Option exercises are not covered.